Pharmacology

PLx Pharma Inc. to Discuss 2020 Fourth Quarter Financial Results on March 12, 2021 Conference Call and Provide Business Update

Thursday, March 4, 2021 - 10:30pm

A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International).

Key Points: 
  • A replay of the conference call will be available for two weeks after the call's completion by dialing (855) 859-2056 (U.S.) or (404) 537-3406 (International).
  • It also reduces the risk of stomach erosions and ulcers, as compared to immediate-release aspirin, common in an acute setting.
  • PLx Pharma Inc. is a late-stage specialty pharmaceutical company focused on its clinically-validated and patent-protected PLxGuard drug delivery platform to provide more effective and safer products.
  • The PLxGuard drug delivery platform works by targeting the release of active pharmaceutical ingredients to various portions of the gastrointestinal (GI) tract.

Mayne Pharma launches another generic oral contraceptive

Thursday, March 4, 2021 - 9:34pm

This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN24 FE, ORTHO CYCLENand ORTHO TRI-CYCLEN.

Key Points: 
  • This is the fourth oral contraceptive launched this calendar year after launching generic versions of LOESTRIN24 FE, ORTHO CYCLENand ORTHO TRI-CYCLEN.
  • Mayne Pharma's CEO Scott Richards said, "We are very pleased to expand our Women's Health portfolio which now covers ~80% of Obstetrician/Gynaecologist oral contraceptive prescription volumes[1] and includes 24 marketed branded generic contraceptives.
  • Mayne Pharma is committed to helping meet the needs of women in the US by providing cost effective, high-quality and novel contraceptive options.
  • "In addition, Mayne Pharma has four women's health pipeline products pending at the FDA including the novel combined oral contraceptive NEXTSTELLIS (E4/DRSP) and a generic version of NUVARING.

United States Active Pharmaceutical Ingredient (API) Market Report 2021: Synthetic Method of Synthesis Dominated the Market with a Share of 58.29% in 2020 - Forecast to 2026 - ResearchAndMarkets.com

Thursday, March 4, 2021 - 2:52pm

The United States Active Pharmaceutical Ingredient Market stood at USD17.81 billion in 2020 and is projected to grow at a CAGR of 9.73% to cross USD31.48 billion by 2026.

Key Points: 
  • The United States Active Pharmaceutical Ingredient Market stood at USD17.81 billion in 2020 and is projected to grow at a CAGR of 9.73% to cross USD31.48 billion by 2026.
  • This can be attributed to growing prevalence of chronic diseases such as cardiovascular diseases, diabetes, cancer, respiratory disorders, among others.
  • The United States Active Pharmaceutical Ingredient Market can be segregated based on method of synthesis, source, distribution channel, therapeutic application, form, molecule type, potency, drug type, region and company.
  • The synthetic method of synthesis dominated the market with a share of 58.29% in 2020 on account of the easy availability of raw materials and easier process for development of active pharmaceutical ingredients.

Sinclair Research Appoints Sandra Love as Director of Safety Pharmacology

Thursday, March 4, 2021 - 2:00pm

Sinclair Research, a leading provider of nonclinical research services, has named Dr. Sandra Love, PhD as Director of Safety Pharmacology.

Key Points: 
  • Sinclair Research, a leading provider of nonclinical research services, has named Dr. Sandra Love, PhD as Director of Safety Pharmacology.
  • For over 20 years, Dr. Love has specialized in providing safety pharmacology research services to small and large biopharmaceutical drug developers.
  • Prior to joining Sinclair Research, Sandra was Director of Pharmacology at Charles River (formerly CitoxLab USA and Xenometrics) where she oversaw the safety pharmacology program, providing guidance on study designs to sponsors and supervising all functions and personnel for the pharmacology group.
  • Sandra brings a depth and breadth of safety pharmacology experience to Sinclair, said Andy Brown, Vice President of Commercial Operations at Sinclair Research.

Bioanalytical Systems, Inc., doing business as Inotiv, to Participate in the H.C. Wainwright Global Life Sciences Virtual Conference

Thursday, March 4, 2021 - 1:33pm

A webcast of the presentation will be available on March 9, 2021, at 7:00 a.m.

Key Points: 
  • A webcast of the presentation will be available on March 9, 2021, at 7:00 a.m.
  • ET through a link that will be posted on theInvestorssection of the Companys website at ir.inotivco.com and will be available for approximately 90 days.
  • Bioanalytical Systems, Inc., doing business as Inotiv, is a pharmaceutical development company providing contract research services and monitoring instruments to emerging pharmaceutical companies and the world's leading drug development companies and medical research organizations.
  • The Company focuses on developing innovative services supporting its clients discovery and development objectives for improved decision-making and accelerated goal attainment.

SIUE School of Pharmacy Adds Medicinal Chemistry Specialization

Thursday, March 4, 2021 - 8:00am

The medicinal chemistry specialization is offered in collaboration with the Department of Pharmacology at the SIU School of Medicine.

Key Points: 
  • The medicinal chemistry specialization is offered in collaboration with the Department of Pharmacology at the SIU School of Medicine.
  • To learn more about the SOP pharmacology and neuroscience cooperative PhD program with a medicinal chemistry specialization, visit siue.edu/pharmacology-neuroscience .
  • The SIUE School of Pharmacy curriculum is an innovative model that offers students a unique combination of classroom education, research, community service and patient care.
  • Established in 2005, the SIUE School of Pharmacy is providing highly trained graduates prepared for the rapidly changing healthcare environment.

Global Tissue Processing Systems Market Forecast to 2027 - COVID-19 Impact and Analysis - ResearchAndMarkets.com

Thursday, March 4, 2021 - 10:59am

The "Tissue Processing Systems Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product, Volume, and End User and Geography" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Tissue Processing Systems Market Forecast to 2027 - COVID-19 Impact and Global Analysis By Product, Volume, and End User and Geography" report has been added to ResearchAndMarkets.com's offering.
  • The report highlights trends prevailing in the global tissue processing systems market, and the factors governing the market growth.
  • On the basis of end user, the tissue processing systems market is segmented into hospitals, pharmaceutical companies, research laboratories, and others.
  • The global tissue processing systems market growth is mainly attributed to as the increasing prevalence of cancer and rising number of diagnostic laboratories.

PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH

Wednesday, March 3, 2021 - 8:00am

OXFORD, England, March 3, 2021 /PRNewswire/ -- PharmaVentures is pleased to announce it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH.

Key Points: 
  • OXFORD, England, March 3, 2021 /PRNewswire/ -- PharmaVentures is pleased to announce it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH.
  • ERA Consultingis a leading strategic product development and regulatory consulting group serving the global biopharmaceutical industry.
  • "This transaction highlights our track record in supporting the sale of specialist pharmaceutical clinical services companies in the pharmaceutical industry," said Dr Fintan Walton, CEO and Founder of PharmaVentures.
  • Sabine Husmann-Holloway, Co-Founder & CEO of ERA Consulting Group, said, "I feel I made an excellent choice in PharmaVentures to serve as my exclusive advisors for the sale of the Company.

PharmaVentures acts as M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH

Wednesday, March 3, 2021 - 8:00am

OXFORD, England, March 3, 2021 /PRNewswire/ --PharmaVentures is pleased to announce it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH.

Key Points: 
  • OXFORD, England, March 3, 2021 /PRNewswire/ --PharmaVentures is pleased to announce it acted as exclusive M&A advisor on the sale of the ERA Consulting Group to PharmaLex GmbH.
  • ERA Consultingis a leading strategic product development and regulatory consulting group serving the global biopharmaceutical industry.
  • "This transaction highlights our track record in supporting the sale of specialist pharmaceutical clinical services companies in the pharmaceutical industry," said Dr Fintan Walton, CEO and Founder of PharmaVentures.
  • Sabine Husmann-Holloway, Co-Founder & CEO of ERA Consulting Group, said, "I feel I made an excellent choice in PharmaVentures to serve as my exclusive advisors for the sale of the Company.

Lixte Biotechnology Announces the Closing of $4.19 Million Registered Direct Offering

Tuesday, March 2, 2021 - 3:30pm

WestPark Capital, Inc. and WallachBeth Capital, LLC acted as co-placement agents for the offering.

Key Points: 
  • WestPark Capital, Inc. and WallachBeth Capital, LLC acted as co-placement agents for the offering.
  • The shares of common stock were offered by Lixte pursuant to a "shelf" registration statement on Form S-3 (File No.
  • Lixte Biotechnology Holdings, Inc. (Nasdaq: LIXT) is a clinical-stage pharmaceutical company dedicated to discovering drugs for more effective treatments for many forms of cancer and other serious common diseases.
  • Lixte has partnered with top medical institutions and leading academic research centers to advance the clinical development of its compounds.